- VernacularTitle:金昌队列人群肝癌疾病负担研究
- Author:
Xiaobin HU
1
;
Yana BAI
1
;
Hongquan PU
2
;
Kai ZHANG
3
;
Ning CHENG
4
;
Haiyan LI
2
;
Xiping SHEN
1
;
Fuxiu LI
2
;
Xiaowei REN
1
;
Jinbing ZHU
2
;
Shan ZHENG
1
;
Minzhen WANG
1
;
Min DAI
3
Author Information
- Publication Type:Journal Article
- MeSH: Aged; China; epidemiology; Cohort Studies; Cost of Illness; Female; Hospitalization; economics; statistics & numerical data; Humans; Liver Neoplasms; economics; mortality; Male; Middle Aged
- From: Chinese Journal of Epidemiology 2016;37(3):321-324
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVETo understand the current status of the disease burden of liver cancer in Jinchang cohort.
METHODSAll the liver cancer death data from 2001 to 2013 and medical records of liver cancer cases from 2001 to 2010 in Jinchang cohort were collected for the analyses of the mortality, standardized mortality, potential years of life lost (PYLL) and working PYLL (WPYLL) associated with liver cancer. Spearman correlation and the average growth rate were used to analyze the trends.
RESULTSA total of 207 liver cancer deaths occurred in Jinchang cohort from 2001 to 2013, accounting for 16.68% of total cancer deaths. There were 259 liver cancer inpatients, accounting for 6.79% of the total cancer cases inpatients, in which 83 died (32.05%). Liver cancer death mainly occurred in males, accounting for 88.89%, and the liver cancer deaths in females accounted for 11.11%. The standardized mortality rate was 42.32/100,000 in males and 15.31/100,000 in females. The growth rate of liver cancer mortality was 5.62% from 2001 to 2013. Liver cancer deaths mainly occurred in age groups 60-69 years (26.57%) and 50-59 years (24.15%). The PYLL was 2906.76 person-years, the average PYLL was 14.04 years. The WPYLL was 1477.00 person-years and the average WPYLL was 7.14 years. The direct economic burden of liver cancer was 6270.78 Yuan per person, 301.75 Yuan per day. The average stay of hospitalization was 21.32 days.
CONCLUSIONThe mortality rate of liver cancer is increasing and the disease burden is still heavy.